D-0100-2021 Class III Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0100-2021 was initiated by Teva Pharmaceuticals USA on Nov 11, 2020 and is designated Class III. Reason for recall: Superpotent Drug: High out-of-specification assay results were obtained during stability testing. The recall status is terminated (terminated Jun 24, 2021). Affected quantity: 12,088 cartons.

Recall details

Product Type
Drugs
Report Date
Nov 25, 2020
Initiation Date
Nov 11, 2020
Termination Date
Jun 24, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
12,088 cartons

Product description

Testosterone Gel 1%, 2.5 grams per unit dose, packaged in 2.5 gram Unit-Dose Packets (NDC 0591-3216-17); 30 Unit-Dose Packets per carton (NDC 0591-3216-30), Rx only, Manufactured by: Actavis Laboratories UT, Inc., Salt Lake City, UT 84108; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054.

Reason for recall

Superpotent Drug: High out-of-specification assay results were obtained during stability testing.

Distribution pattern

Product was distributed Nationwide in the USA.

Code information

Lot Number: 1351104, Exp 08/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0100-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0100-2021. Report a data issue: hello@regdatalab.com.